Teva Pharmaceutical Industries LTD TEVA
We take great care to ensure that the data presented and summarized in this overview for TEVA PHARMACEUTICAL INDUSTRIES LTD is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding TEVA
View all-
Black Rock Inc. New York, NY43MShares$715 Million0.02% of portfolio
-
Ion Asset Management Ltd. George Town, Grand Cayman, E939MShares$650 Million39.53% of portfolio
-
Clal Insurance Enterprises Holdings LTD Tel Aviv, L337.8MShares$629 Million5.98% of portfolio
-
Menora Mivtachim Holdings Ltd.29.2MShares$486 Million2.92% of portfolio
-
Exor Capital LLP London, X027.9MShares$463 Million12.23% of portfolio
-
Phoenix Holdings Ltd. Givatayim, L327.5MShares$457 Million6.56% of portfolio
-
Migdal Insurance & Financial Holdings Ltd.26.3MShares$438 Million5.68% of portfolio
-
Rubric Capital Management LP New York, NY25.6MShares$425 Million11.25% of portfolio
-
Harel Insurance Investments & Financial Services Ltd.22.1MShares$367 Million4.44% of portfolio
-
State Street Corp Boston, MA17.3MShares$288 Million0.01% of portfolio
Latest Institutional Activity in TEVA
Top Purchases
Top Sells
About TEVA
Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, and internationally. The company offers sterile products, hormones, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams. It also develops, manufactures, and sells active pharmaceutical ingredients. In addition, it focuses on the central nervous system, pain, respiratory, and oncology areas. Its products in the central nervous system include Copaxone for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine; and AUSTEDO for the treatment of tardive dyskinesia and chorea associated with Huntington disease. The company's products in the respiratory market comprise ProAir, QVAR, ProAir Digihaler, AirDuo Digihaler, and ArmonAir Digihaler, BRALTUS, CINQAIR/CINQAERO, DuoResp Spiromax, and AirDuo RespiClick/ArmonAir RespiClick for the treatment of asthma and chronic obstructive pulmonary disease. Its products in the oncology market include Bendeka, Treanda, Granix, Trisenox, Lonquex, and Tevagrastim/Ratiograstim. Teva Pharmaceutical Industries Limited has a collaboration MedinCell for the development and commercialization of multiple long-acting injectable products, a risperidone suspension for the treatment of patients with schizophrenia. The company was founded in 1901 and is headquartered in Tel Aviv-Yafo, Israel.
Insider Transactions at TEVA
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Jun 12
2025
|
Eliyahu Sharon Kalif EVP, Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
55,775
-12.15%
|
$948,175
$17.08 P/Share
|
Jun 06
2025
|
Janet S. Vergis |
BUY
Exercise of conversion of derivative security
|
Direct |
9,632
+11.56%
|
-
|
Jun 06
2025
|
Varda Shalev |
BUY
Exercise of conversion of derivative security
|
Direct |
9,632
+29.97%
|
-
|
Jun 06
2025
|
Tal Zvi Zaks |
BUY
Exercise of conversion of derivative security
|
Direct |
9,632
+14.08%
|
-
|
Jun 06
2025
|
Perry Nisen |
BUY
Exercise of conversion of derivative security
|
Direct |
9,632
+8.38%
|
-
|
Jun 06
2025
|
Ronit Satchi Fainaro |
BUY
Exercise of conversion of derivative security
|
Direct |
9,632
+8.96%
|
-
|
Jun 06
2025
|
Rosemary A Crane |
BUY
Exercise of conversion of derivative security
|
Direct |
9,632
+7.84%
|
-
|
Jun 06
2025
|
Amir Elstein |
BUY
Exercise of conversion of derivative security
|
Direct |
9,632
+0.46%
|
-
|
Jun 06
2025
|
Gerald M Lieberman |
BUY
Exercise of conversion of derivative security
|
Direct |
9,632
+7.69%
|
-
|
Jun 06
2025
|
Sol J Barer |
BUY
Exercise of conversion of derivative security
|
Direct |
17,158
+3.87%
|
-
|
Jun 06
2025
|
Roberto Mignone |
BUY
Exercise of conversion of derivative security
|
Direct |
9,632
+8.38%
|
-
|
Jun 03
2025
|
Matthew Shields EVP, Global Operations |
SELL
Open market or private sale
|
Direct |
6,206
-38.32%
|
$105,502
$17.02 P/Share
|
Jun 03
2025
|
Matthew Shields EVP, Global Operations |
BUY
Exercise of conversion of derivative security
|
Direct |
16,195
+50.0%
|
-
|
May 08
2025
|
Mark Sabag |
SELL
Open market or private sale
|
Direct |
337,915
-69.12%
|
$6,082,470
$18.04 P/Share
|
Mar 05
2025
|
Amir Weiss Chief Accounting Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,566
+10.55%
|
-
|
Mar 05
2025
|
Eliyahu Sharon Kalif EVP, Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
21,390
+4.45%
|
-
|
Mar 05
2025
|
Mark Sabag |
BUY
Exercise of conversion of derivative security
|
Direct |
23,765
+4.64%
|
-
|
Mar 05
2025
|
Richard Daniell Exec. VP, European Commercial |
SELL
Open market or private sale
|
Direct |
119,725
-58.52%
|
$1,795,875
$15.91 P/Share
|
Mar 05
2025
|
Richard Daniell Exec. VP, European Commercial |
BUY
Exercise of conversion of derivative security
|
Direct |
22,576
+15.91%
|
-
|
Mar 05
2025
|
David R. Mc Avoy EVP, Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
1,677
-12.34%
|
$25,155
$15.91 P/Share
|
Last 12 Months Summary
Exercise of conversion of derivative security | 1.57M shares |
---|
Open market or private sale | 1.57M shares |
---|